By Patrick Daly
First-line treatment with golcadomide, a first-in-class oral cereblon E3 ligase modulator (CELMoD), plus Pola-RCHP resulted in predictable and manageable safety outcomes without compromising Pola-RCHP dose intensity for patients with aggressive B-cell lymphoma in the ongoing GOLSEEK-1 trial.
In addition, golcadomide plus Pola-RCHP yielded high rates of durable complete metabolic response and minimal residual disease negativity, and a “promising” 12-month progression-free survival (PFS) rate, according to phase 1b data presented by Marc S. Hoffmann, MD, of the University of Kansas Cancer Center, Kansas City, at the 2026 ASCO® Annual Meeting.
The presentation covered 57 patients, of which 86% had high-risk disease and 84% had diffuse large B-cell lymphoma with unspecified histology. Among the patients, 28 received golcadomide 0.2 mg and 29 received golcadomide 0.4 mg. At data cutoff, grade 3 or 4 treatment-emergent adverse events occurred in 95% of patients, including neutropenia in 86% and anemia in 39%.
After a median follow-up of 15.5 months, the complete metabolic response rate was 69% in patients assigned to the 0.2 mg dose, and 82% in patients assigned to the 0.4 mg dose. The 12-month duration of response and PFS rates were 92% and 88% with golcadomide 0.2 mg, and 96% and 96% with golcadomide 0.4 mg, respectively.
The data continue to show that golcadomide plus standard of care regimens like R-CHOP or Pola-RCHP has the potential to improve outcomes for patients with high-risk aggressive B-cell lymphoma in the first-line setting, Dr. Hoffman and colleagues wrote.
Funding for this study was provided by BMS.
Leave feedback about this